OTCMKTS:GMXAY GENMAB A/S/S (GMXAY) Stock Price, News & Analysis $50.60 -0.75 (-1.46%) As of 11/20/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsOwnership About GENMAB A/S/S Stock (OTCMKTS:GMXAY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GENMAB A/S/S alerts:Sign Up Key Stats Today's Range$50.24▼$51.7250-Day Range$32.47▼$57.0652-Week Range$12.10▼$19.00Volume2.90 million shsAverage Volume48,553 shsMarket CapitalizationN/AP/E Ratio19.42Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1999, it discovers and develops antibody-based medicines for the treatment of cancer and other serious diseases. Its research uses proprietary antibody technologies, including platforms designed to create multispecific antibodies and antibody-drug conjugates. Genmab’s products and development programs include treatments developed independently and with pharmaceutical partners. Its collaborations have helped bring medicines such as Darzalex (daratumumab), Epkinly/Tepkinly (epcoritamab) and Tivdak (tisotumab vedotin) to market. The company also advances a pipeline of investigational antibody therapies. Genmab works with partners to develop and commercialize medicines internationally, serving patients across multiple regions. Co-founder Jan van de Winkel has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Receive GMXAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GENMAB A/S/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMXAY Stock News HeadlinesA little-known biotech’s high-stakes cancer bet just paid off and its shares doubledNovember 3, 2026 | msn.comGenmab and AbbVie’s Epkinly combo improves PFS in second-line DLBCL trialJune 30, 2026 | msn.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 22 at 1:00 AM | Paradigm Press (Ad)Genmab A/S ADRApril 13, 2026 | barrons.comGenmab (GMAB) fuels confidence based on upcoming Epkinly and Petosemtamab readoutsMarch 26, 2026 | msn.comA Peek at Genmab's Future EarningsFebruary 16, 2026 | benzinga.comGenmab: Darzalex Growth Fuels Rally, Upside Is TightJanuary 23, 2026 | seekingalpha.comGenmab (GMAB)’s future potential underappreciated by marketJanuary 21, 2026 | msn.comSee More Headlines GMXAY Stock Analysis - Frequently Asked Questions How have GMXAY shares performed this year? GENMAB A/S/S's stock was trading at $33.42 at the beginning of 2026. Since then, GMXAY stock has increased by 51.4% and is now trading at $50.60. How do I buy shares of GENMAB A/S/S? Shares of GMXAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:GMXAY CIKN/A Webwww.genmab.com Phone45 70 20 27 28FaxN/AEmployees1,660Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio19.42 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (OTCMKTS:GMXAY) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe warning signs most investors see too lateDr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. ...Weiss Ratings | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENMAB A/S/S Please log in to your account or sign up in order to add this asset to your watchlist. Share GENMAB A/S/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.